Abstract
Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is a nonsteroid, has anti-inflammatory activity, and has demonstrated efficacy in reducing symptoms of atopic dermatitis in adult and paediatric patients when applied topically. Compared with vehicle, topical pimecrolimus 1.0% cream was significantly more effective at reducing symptoms of atopic dermatitis, as measured by the Eczema Area and Severity Index (EASI), in infants aged 3 to 23 months, children aged 2 to 17 years and adults. The median reductions from baseline in the total EASI score in adults after treatment with pimecrolimus 1.0% or corresponding vehicle twice daily for 3 weeks were 47 and 0%, respectively. In infants and children, treatment with pimecrolimus 1.0% twice daily for 6 weeks resulted in significant decreases in mean EASI scores compared with vehicle. The severity of pruritus was significantly reduced in patients of all age groups after topical treatment with pimecrolimus 1.0% cream. Compared with vehicle, the incidence of eczematous flares was also reduced by intermittent long-term use of topical pimecrolimus 1.0% in adults, children and infants. Sixty percent of children treated with pimecrolimus for 1 year completed the first 6 months of treatment w...Continue Reading
References
Aug 1, 1991·Pediatric Clinics of North America·J M Hanifin
Dec 1, 1987·Journal of the American Academy of Dermatology·J L SeymourM C Milligan
May 1, 1974·The British Journal of Dermatology·J J LeydenA M Kligman
Sep 26, 1997·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·D Y LeungS L Spector
Dec 9, 1997·The British Journal of Dermatology·J G MeingassnerA Stütz
Apr 8, 1998·BMJ : British Medical Journal·P H Howarth
May 16, 1998·BMJ : British Medical Journal·P S Friedmann
Jul 29, 1998·Archives of Dermatology·E J Van LeentJ D Bos
Nov 10, 1998·Archives of Dermatological Research·T HultschJ Knop
Jan 20, 1999·The Journal of Allergy and Clinical Immunology·H WilliamsS K Weiland
Feb 17, 1999·The British Journal of Dermatology·U MrowietzE Christophers
Sep 1, 1999·The British Journal of Dermatology·M GrassbergerG Zenke
May 3, 2000·The British Journal of Dermatology·G NeckermannJ G Meingassner
Jun 28, 2000·Contact Dermatitis·C Queille-RousselJ P Ortonne
Nov 4, 2000·Expert Opinion on Investigational Drugs·C PaulA Stuetz
Mar 22, 2001·The British Journal of Dermatology·C Queille-RousselJ P Ortonne
Mar 30, 2001·Nature Genetics·W O CooksonJ I Harper
Apr 12, 2001·The British Journal of Dermatology·J HarperP Burtin
Apr 12, 2001·The British Journal of Dermatology·T LugerJ D Bos
Jul 7, 2001·American Journal of Therapeutics·A M Fendrick, J L Baldwin
Feb 9, 2002·Dermatology : International Journal for Clinical and Investigative Dermatology·Edwin J M Van LeentJan D Bos
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·K Wellington, C M Spencer
Citations
Feb 1, 2003·PharmacoEconomics·Roman SchiffnerWilhelm Stolz
Nov 25, 2004·Experimental Dermatology·M GrassbergerT A Luger
Jan 25, 2005·American Journal of Clinical Dermatology·Keri Wellington, Stuart Noble
Aug 13, 2005·The Journal of Dermatological Treatment·Mark LingKen Abrams
Dec 3, 2009·Journal of Neurosurgery. Spine·Berker CemilIbrahim Tekdemir
Sep 14, 2011·The Mount Sinai Journal of Medicine, New York·Andrew SohnGary Goldenberg
Aug 21, 2003·American Journal of Clinical Dermatology·Gil Yosipovitch, Alan Fleischer
Oct 20, 2004·The Journal of Dermatology·Marcelo H GrunwaldBoaz Amichai
Feb 7, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Richard G B LangleyCarle Paul
Sep 15, 2009·Clinical and Experimental Dermatology·J-C Li, A-E Xu
Jan 16, 2009·Basic & Clinical Pharmacology & Toxicology·Yunes PanahiMohammad Mehdi Naghizadeh
Jun 19, 2004·The Journal of Dermatological Treatment·T A LugerJ D Bos
Sep 6, 2003·Advances in Therapy·Alexander K C Leung, Kirk A Barber
Jul 21, 2011·Experimental Dermatology·Roland AschoffMichael Meurer
Jun 11, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·Harald GollnickUNKNOWN STABIEL study group
Mar 7, 2013·Expert Opinion on Pharmacotherapy·Jean Ayer, Helen S Young
Apr 12, 2006·American Journal of Clinical Dermatology·Jann LübbeUNKNOWN NOBEL (New Online Based ELidel) Study Group
Apr 2, 2003·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·R Niedner
Nov 17, 2011·Cutaneous and Ocular Toxicology·Yunes PanahiAmirhossein Sahebkar
Jul 24, 2013·Expert Opinion on Drug Metabolism & Toxicology·Hanna PruchaClaudia Traidl-Hoffmann
Jul 11, 2006·Current Allergy and Asthma Reports·Jonathan M Spergel, Donald Y M Leung
Aug 24, 2006·International Archives of Allergy and Immunology·Anton StuetzJosef G Meingassner
Sep 15, 2005·Rheumatology·A Tlacuilo-ParraM Salazar-Páramo
Jan 8, 2003·PharmacoEconomics·Andrew S Kemp
Aug 11, 2004·American Journal of Clinical Dermatology·Michael IskedjianThomas R Einarson
Mar 4, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·T Zuberbier, M Bräutigam
Jan 8, 2021·Therapeutics and Clinical Risk Management·Celina DubinEmma Guttman-Yassky